These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 34846878)
41. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells. Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766 [TBL] [Abstract][Full Text] [Related]
42. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251 [TBL] [Abstract][Full Text] [Related]
43. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway. Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444 [TBL] [Abstract][Full Text] [Related]
44. Solution equilibrium, structural and cytotoxicity studies on Ru(η Dömötör O; Kiss MA; Gál GT; May NV; Spengler G; Nové M; Gašparović AČ; Frank É; Enyedy ÉA J Inorg Biochem; 2020 Jan; 202():110883. PubMed ID: 31689626 [TBL] [Abstract][Full Text] [Related]
45. Anticancer activity and mechanism of bis-pyrimidine based dimetallic Ru(II)(η Bhatti MZ; Ali A; Duong HQ; Chen J; Rahman FU J Inorg Biochem; 2019 May; 194():52-64. PubMed ID: 30831390 [TBL] [Abstract][Full Text] [Related]
48. Ruthenium(II) complexes as bioorthogonal two-photon photosensitizers for tumour-specific photodynamic therapy against triple-negative breast cancer cells. Lin M; Zou S; Liao X; Chen Y; Luo D; Ji L; Chao H Chem Commun (Camb); 2021 May; 57(36):4408-4411. PubMed ID: 33949487 [TBL] [Abstract][Full Text] [Related]
54. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042 [TBL] [Abstract][Full Text] [Related]
55. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties. Ludwig G; Kaluđerović GN; Bette M; Block M; Paschke R; Steinborn D J Inorg Biochem; 2012 Aug; 113():77-82. PubMed ID: 22698819 [TBL] [Abstract][Full Text] [Related]
58. Differences in Stability, Cytotoxicity, and Mechanism of Action of Ru(II) and Pt(II) Complexes of a Bidentate N,O Donor Ligand. Maji M; Acharya S; Maji S; Purkait K; Gupta A; Mukherjee A Inorg Chem; 2020 Jul; 59(14):10262-10274. PubMed ID: 32585099 [TBL] [Abstract][Full Text] [Related]
59. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets. Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850 [TBL] [Abstract][Full Text] [Related]
60. Exploring the potential of ruthenium(II)-phosphine-mercapto complexes as new anticancer agents. Palmeira-Mello MV; Costa AR; de Oliveira LP; Blacque O; Gasser G; Batista AA Dalton Trans; 2024 Jul; 53(26):10947-10960. PubMed ID: 38895770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]